<DOC>
	<DOCNO>NCT00645554</DOCNO>
	<brief_summary>The purpose open-label , single dose , two-treatment , two-period , cross-over study evaluate pharmacokinetic profile tolerability galantamine oral solution galantamine tablet .</brief_summary>
	<brief_title>A Single Dose , Cross-over Bioequivence Study Comparing Galantamine IR ( Immediate Release ) Table Galantmine OS ( Oral Solution ) Healthy Volunteers</brief_title>
	<detailed_description>This open-label , single dose , two-treatment , two-period , cross-over study evaluate pharmacokinetic profile tolerability galantamine oral solution galantamine tablet . All patient healthy male patient 18-45 year old BWI ( Body Weight Index ) 18-28 kg/m2 . All patient must sign informed consent enrol . 24 patient randomize study . The duration study 9 day . All patient must stay site unit 12 hour single oral administration otherwise patient could stay home must return site specific date time . The day dose day ( baseline ) , patient randomize one two group administer either 4mg galantamine oral solution ( 1ml ) galantamine tablet ( 1 tablet ) . After 7-day washout period , patient cross receive formulation . Pharmacokinetic observation last 32 hour dose . Plasma collect immediately dose 0.25 , 0.5 , 0.75 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 32 hour dose determine plasma concentration galantamine . Safety tolerance evaluation last Day 9 . Safety evaluation include adverse event , vital sign , physical examination , electrocardiogram laboratory test . On study Day 1 , patient take either 4mg galantamine oral solution ( 1ml ) 4mg galantamine tablet ( 1 tablet ) . After 7-day washout period , Day 8 , patient cross take formulation , dosage administration .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>All patient must meet following criterion : body weight index 1828 kg/m2 Patients deem healthy base physical examination , medical history , vital sign , electrocardiogram result clinical laboratory test All patient must able read understand content informed consent must sign prior trialspecific procedure do . Patients meet one follow criterion include study : patient us disallow medicine , prescribed medication within last 2 week OTC drug within last week prior dose ( least 5 half life drug ingest ) . Patients take nonprescribed systemic topical medication may still enter study , , opinion investigator , medication interfere study procedure compromise safety The subject history alcohol drug abuse Patient treat investigational drug within 30 day prior screen Patient know hypersensitivity galantamine history severe drug allergy hypersensitivity Patient serious illness liver renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , metabolic chronic disturbance Patient donate blood within 60 day prior dose Patient moderate severe smoker smoke 3 cigarette , exsmokers cease smoke least 3 month prior dose Patient , opinion investigator , unlikely comply clinical study protocol unsuitable reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Galantamine oral solution</keyword>
	<keyword>Galantamine tablet</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>